Peripheral Neuropathy is Associated With Increased Serum Levels of Uric Acid in Type 2 Diabetes Mellitus

Παπάνας, Νικόλαος; Katsiki, Niki; Παπαθεοδώρου, Κωνσταντίνος; Δημητρίου, Μαρία; Papazoglou, Dimitrios; Gioka, T.; Maltezos, Efstratios

doi:10.1177/0003319710394164

Cited by 64 publications

(63 citation statements)

References 46 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, previous studies found that elevated levels of HbA1c, FPG, TG, and LDL-C, but declined levels of HDL-C have been implicated in the progression of DPN [19][20][21].…”

Section: Discussionmentioning

confidence: 90%

Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy

Xie

Zheng

et al. 2016

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…Also, previous studies found that elevated levels of HbA1c, FPG, TG, and LDL-C, but declined levels of HDL-C have been implicated in the progression of DPN [19][20][21].…”

Section: Discussionmentioning

confidence: 90%

Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy

Xie

Zheng

et al. 2016

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…Serum hs-CRP is independently associated with development of diabetic neuropathy and diabetic foot ulcers [37]. On the other hand, Herder et al [38] observed no associations between CRP and neuropathy in a population-based survey of older people with T2DM.…”

Section: Discussionmentioning

confidence: 99%

Baseline High-Sensitivity C-Reactive Protein Predicts Macrovascular and Microvascular Complications of Type 2 Diabetes: A Population-Based Study

et al. 2018

View full text Add to dashboard Cite

Background/Aims: This prospective study is aimed at examining the predictive value of high-sensitivity C-reactive protein (hs-CRP) for coronary heart disease (CHD) events and microvascular complications of type 2 diabetes mellitus (T2DM). Methods: A population-based study (NCT02958579) was conducted on 1,301 participants with T2DM (mean follow-up of 7.5 years). Risk assessment for vascular events was done at baseline, and serum hs-CRP was measured. End points of this study include CHD events, diabetic retinopathy, neuropathy, and diabetic kidney disease. Individuals with unavailable data or hs-CRP >20 mg/L were excluded. The discrimination and reclassification improvement of study end points were tested after addition of hs-CRP to traditional risk factors. Results: Median serum hs-CRP was 2.00 ranging from 0.1 to 17 mg/L. Hazards ratio of each SD increment in baseline hs-CRP was 1.028 (1.024–1.032) for CHD, 1.025 (1.021–1.029) for diabetic neuropathy, 1.037 (1.030–1.043) for diabetic retinopathy, and 1.035 (1.027–1.043) for diabetic kidney disease. The addition of hs-CRP to traditional risk factors of vascular complications of T2DM improved discrimination of all end points (p < 0.001). Net reclassification improvement ranged from 8% for diabetic neuropathy to 31% for diabetic kidney disease (p < 0.05). Conclusion: Baseline hs-CRP predicts both of CHD events and microvascular complications of patients with T2D.

show abstract

“…Moreover, serum levels of omentin, an adipokine with anti-inflammatory, insulin-sensitizing, and cardioprotective properties, were reduced in T2D individuals with DSPN, independently of established risk factors of polyneuropathy [89]. In T2D, there is also evidence of increased serum uric acid in the presence of DSPN [93,94]. Future studies should clarify the temporal sequence and causality of these associations.…”

Section: Inflammationmentioning

confidence: 97%

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

2015

View full text Add to dashboard Cite

■ AbstractDistal symmetric sensorimotor polyneuropathy (DSPN) is the most common neurological manifestation in diabetes. Major risk factors of DSPN include diabetes duration, hyperglycemia, and age, followed by prediabetes, hypertension, dyslipidemia, and obesity. Height, smoking, insulin resistance, hypoinsulinemia, and others represent an additional risk. Importantly, hyperglycemia, hypertension, dyslipidemia, obesity, and smoking are modifiable. Stringent glycemic control has been shown to be effective in type 1, but not to the same extent in type 2 diabetes. Antilipidemic treatment, especially with fenofibrate, and multi-factorial intervention have produced encouraging results, but more experience is necessary. The major comorbidities of DSPN are depression, autonomic neuropathy, peripheral artery disease, cardiovascular disease, nephropathy, retinopathy, and medial arterial calcification. Knowledge of risk factors and comorbidities has the potential to enrich the therapeutic strategy in clinical practice as part of the overall medical care for patients with neuropathy. This article provides an updated overview of DSPN risk factors and comorbidities.

show abstract

Peripheral Neuropathy is Associated With Increased Serum Levels of Uric Acid in Type 2 Diabetes Mellitus

Cited by 64 publications

References 46 publications

Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy

Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy

Baseline High-Sensitivity C-Reactive Protein Predicts Macrovascular and Microvascular Complications of Type 2 Diabetes: A Population-Based Study

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

Contact Info

Product

Resources

About